The Short Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and rest of the world. According to DelveInsight, the forecasted patient population of SBS will increase at a CAGR of 1.73% from 2015 to 2020 and the worldwide SBS market is estimated to be 2.69 billion by 2020.
The treatment options are complex and varied. The specific treatment plan may be highly individualized and can include Total Parental Nutrition (TPN) support, which involves use of oral rehydration solutions, parenteral nutrition and enteral nutrition. Gattex (Teduglutide) is currently the first non-surgical treatment for short bowel syndrome (SBS), which is predicted to improve the daily, lives of the patients and is the third approved therapy by USFDA
Key Coverage and Benefits:
•
• The report will help in developing business strategies by understanding the trends shaping and driving the global Short Bowel Syndrome
• Identifying patient populations in the global Short Bowel Syndrome market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Short Bowel Syndrome therapeutics in each of the markets covered.
• To understand the future market competition in the global Short Bowel Syndrome therapeutics market and Insightful review of the key market drivers and barriers.
Scope of the Report:
• Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Middle Eastern Countries and rest of the word from 2010-2020.
• It also provides Market size of Short Bowel Syndrome for United States, EU5, Middle Eastern Countries from 2010 and forecasted Market size to 2020
'
Table of Contents
Short Bowel syndrome
Disease overview:
Pathophysiology:
Symptoms of disease:
Etiology of disease
Diagnosis of disease
Treatment of disease
Overview of Marketed drugs
Zorbtive Description
Mechanism of Action
Pharmacokinetics Properties
Marketed Details
United States
Patent Information
Patents Details
NutreStore Description
Mechanism of Action
Pharmacodynamic Properties
Pharmacokinetics Properties
Marketed Details
United States
Gattex Description
Mechanism of Action
Pharmacodynamics Properties
Pharmacokinetics Properties
Marketed Details
United States
Europe
Patent Information
Patent Exclusivity Expiry Assessment United States (US)
Patents Details
Historical and Forecasted sales of marketed molecules in the Global Short Bowel Syndrome Market
Global Epidemiology of Short Bowel Syndrome Forecasted to 2020
Global Market size (2011-2014)
Global Forecasted Market size (2015-2020)
Global Market Size by Geography
Market size of US (2011-2014)
Forecasted Market size of US (2015-2020)
Market size of Europe
Market size of Germany (2011-2014)
Forecasted Market size of Germany (2015-2020)
Market size of United Kingdom (2011-2014)
Forecasted Market size of United Kingdom (2015-2020)
Market size of France (2011-2014)
Forecasted Market size of France (2015-2020)
Market size of Italy (2011-2014)
Forecasted Market size of Italy (2015-2020)
Market size of Spain (2011-2014)
Forecasted Market size of Spain (2015-2020)
Market size of Japan (2011-2014)
Forecasted Market Size of Japan (2015-2020)
Market size of ROW (2011-2014)
Forecasted Market size of ROW (2015-2020)
Appendix
Report Methodology
Consulting Services
Disclaimer
Report Purchase Options
About DelveInsight
List of Tables
Table 1: Zorbtive, Description
Table 2: Zorbtive, Marketed Details United States (US)
Table 3: Zorbtive, Patent Number Specific Patent Expiry in US (Year), 2015
Table 4: Zorbtive, Patent Details for US
Table 5: NutreStore, Description
Table 6: NutreStore, Marketed Details United States (US)
Table 7: Gattex, Description
Table 8: Gattex, Marketed Details United States (US)
Table 9: Gattex, Marketed Details Europe (EU)
Figure 10: Gattex, Patent Number Specific Patent Expiry (Year), 2015
Table 11: Gattex, Patent Number Specific Patent Expiry in US (Year), 2015
Table 12: Gattex, Patent Exclusivity Expiry (Year), 2015
Table 13: Gattex, Patent (US5789379 A) Details for US
Table 14: Gattex, Patent (US 7056886 B2) Details for US
Table 15: Gattex, Patent (US 7847061 B2) Details for US
Table 16: Short Bowel Syndrome Gattex Drug Sales (USD Millions), (2014-2020)
Table 17: Global Epidemiology of Short Bowel Syndrome (2011-2020)
Table 18: Short Bowel Syndrome Global Market Size (USD Millions), (2011-2014)
Table 19: Short Bowel Syndrome Global Market Size (USD Millions), (2015-2020)
Table 20: Short Bowel Syndrome US Market Size (USD Millions), (2011-2014)
Table 21: Short Bowel Syndrome US Market Size (USD Millions), (2015-2020)
Table 22: Short Bowel Syndrome United Kingdom Market Size (USD Millions), (2011-2014)
Table 23: Short Bowel Syndrome Germany Market Size (USD Millions), (2015-2020)
Table 24: Short Bowel Syndrome United Kingdom Market Size (USD Millions), (2011-2014)
Table 25: Short Bowel Syndrome United Kingdom Market Size (USD Millions), (2015-2020)
Table 26: Short Bowel Syndrome France Market Size (USD Millions), (2011-2014)
Table 27: Short Bowel Syndrome France Market Size (USD Millions), (2015-2020)
Table 28: Short Bowel Syndrome Italy Market Size (USD Millions), (2011-2014)
Table 29: Short Bowel Syndrome Italy Market Size (USD Millions), (2015-2020)
Table 30: Short Bowel Syndrome Spain Market Size (USD Millions), (2011-2014)
Table 31: Short Bowel Syndrome Spain Market Size (USD Millions), (2015-2020)
Table 32: Short Bowel Syndrome Japan Market Size (USD Millions), (2011-2014)
Table 33: Short Bowel Syndrome Japan Market Size (USD Millions), (2015-2020)
Table 34: Short Bowel Syndrome ROW Market Size (USD Millions), (2011-2014)
Table 35: Short Bowel Syndrome ROW Market Size (USD Millions), (2015-2020)
List of Figures
Figure 1: Short Bowel Syndrome Gattex Drug Sales (USD Millions), (2011-2014)
Figure 2: Global Epidemiology of Short Bowel Syndrome (2011-2020)
Figure 3: Short Bowel Syndrome Global Market Size (USD Millions), (2011-2014)
Figure 4: Short Bowel Syndrome Global Market Size (USD Millions), (2015-2020)
Figure 5: Short Bowel Syndrome US Market Size (USD Millions), (2011-2014)
Figure 6: Short Bowel Syndrome US Market Size (USD Millions), (2015-2020)
Figure 7: Short Bowel Syndrome Germany Market Size (USD Millions), (2011-2014)
Figure 8: Short Bowel Syndrome Germany Market Size (USD Millions), (2015-2020)
Figure 9: Short Bowel Syndrome United Kingdom Market Size (USD Millions), (2011-2014)
Figure 10: Short Bowel Syndrome United Kingdom Market Size (USD Millions), (2015-2020)
Figure 11: Short Bowel Syndrome France Market Size (USD Millions), (2011-2014)
Figure 12: Short Bowel Syndrome France Market Size (USD Millions), (2015-2020)
Figure 13: Short Bowel Syndrome Italy Market Size (USD Millions), (2011-2014)
Figure 14: Short Bowel Syndrome Italy Market Size (USD Millions), (2015-2020)
Figure 15: Short Bowel Syndrome Spain Market Size (USD Millions), (2011-2014)
Figure 16: Short Bowel Syndrome Spain Market Size (USD Millions), (2015-2020)
Figure 17: Short Bowel Syndrome Japan Market Size (USD Millions), (2011-2014)
Figure 18: Short Bowel Syndrome Japan Market Size (USD Millions), (2015-2020)
Figure 19: Short Bowel Syndrome ROW Market Size (USD Millions), (2011-2014)
Figure 20: Short Bowel Syndrome ROW Market Size (USD Millions), (2015-2020)
NPS Pharmaceuticals
Shire
